Retatrutide and trizepatide constitute a new class of medications that act on both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These multifunctional receptor https://elodievxbh306669.dailyblogzz.com/39269304/recent-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide